sulbutiamine (Arcalion)

a glutamatergic, dopaminergic, and neurotropic agent which in animals improved learning ability & resistance to fatigue; structure in first source

Also Known As:

Arcalion; 2-isobutyrylthiamine disulfide; Enerion; S 5007; Surmenalit; bis(2-(isobutyryloxy)ethyl-1-N-((4-amino-2-methylpyrimidin-5-yl)methyl)formamido-2-propene-1-yl)disulfide; sulbuthiamine; sulbutiamin; Propanoic acid, 2-methyl-, dithiobis(3-(1-(((4-amino-2-methyl-5-pyrimidinyl)methyl)formylamino)ethylidene)-3,1-propanediyl) ester

Networked: 23 relevant articles (5 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kang, Kui Dong: 2 articles (01/2011 - 11/2010)
2.	Majid, Aman Shah Abdul: 2 articles (01/2011 - 11/2010)
3.	Ollat, H: 2 articles (03/2007 - 03/2000)
4.	Fedotova, A V: 2 articles (11/2003 - 01/2003)
5.	Gordeev, S A: 2 articles (11/2003 - 01/2003)
6.	Bartlett, Michael G: 1 article (01/2020)
7.	Bettendorff, Lucien: 1 article (01/2020)
8.	Byrnes, Charnel C: 1 article (01/2020)
9.	Carrera-Bastos, Pedro: 1 article (01/2020)
10.	Jonus, Hunter C: 1 article (01/2020)

Related Diseases

1.	Fatigue 08/01/2017 - "Sulbutiamin appears to be effective in treating fatigue in MS; particularly in patients who were on some DMT, but not on those who were not. " 08/01/2017 - "This observation may encourage further evaluations of the efficacy of sulbutiamine on fatigue in MS." 10/01/1999 - "[Treatment of chronic postinfectious fatigue: randomized double-blind study of two doses of sulbutiamine (400-600 mg/day) versus placebo]." 08/01/2017 - "Sulbutiamine shows promising results in reducing fatigue in patients with multiple sclerosis." 08/01/2017 - "Whereas several clinical trials have demonstrated the beneficial effects of sulbutiamine in patients with asthenia, there have been no reports on the effects of sulbutiamine on fatigue in patients with MS. Our study was designed to evaluate the short-term effects of sulbutiamine on fatigue in patients with MS. Patients were included if fatigue was one of their three predominant symptoms. "
2.	Asthenia 06/17/2022 - "The results of our review indicate the high efficacy and safety of sulbutiamine in the treatment of asthenia. " 01/01/2003 - "Enerion was used in the treatment of 40 patients with psychovegetative syndrome and asthenia. " 01/01/2003 - "[Use of enerion in psychovegetative syndrome with pronounced asthenia]." 03/01/1999 - "This article reviews the current knowledge on the effects of sulbutiamine in animal models and in various forms of human asthenia." 11/01/2003 - "Enerion therapy decreased the degree of psychoautonomic syndrome and asthenia and improved cognitive functions."
3.	Diabetic Neuropathies (Diabetic Neuropathy) 01/01/2002 - "Sulbutiamine objectively improved peripheral nerve function in diabetic polyneuropathy although the symptom score did not improve, possibly due to the short duration of the study." 01/01/2002 - "Effects of sulbutiamine on diabetic polyneuropathy: an open randomised controlled study in type 2 diabetics."
4.	Multiple Sclerosis 08/01/2017 - "Sulbutiamine shows promising results in reducing fatigue in patients with multiple sclerosis."
5.	Erectile Dysfunction 01/01/2005 - "Thus, psychogenic erectile dysfunction can be effectively treated with enerion." 01/01/2005 - "Twenty patients with psychogenic erectile dysfunction received the drug enerion (Hungary). " 01/01/2005 - "[Clinical efficacy of the drug enerion in the treatment of patients with psychogenic (functional) erectile dysfunction]."

Related Drugs and Biologics

1.	Fluoxetine (Prozac)
2.	Cytidine Diphosphate Choline (Citicoline)
3.	OSU 6162
4.	Thiamine (Aneurin)
5.	Cholinergic Agents (Cholinergics)
6.	Vitamin B Complex (B Vitamins)
7.	Oxygen (Dioxygen)
8.	Glucose (Dextrose)
9.	sulbutiamine (Arcalion)
10.	Nootropic Agents (Nootropics)

Related Therapies and Procedures

1.	Therapeutics
2.	Intraperitoneal Injections